Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Post COVID .

Melbourne ME/CFS Collaboration

Precision research program to identify the unique biology of individuals and the unifying biological pathways of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS)

Core Aims

What we hope to achieve

Philosophy

Our fundamental philosophy

Science Team

List of scientific collaborators

The Research

Current research projects

About the Melbourne ME/CFS Collaboration

Established in 2020, the Melbourne ME/CFS Collaboration is directed by Christopher W. Armstrong, PhD.

The Melbourne ME/CFS Collaboration  seeks to characterize the unifying biological pathways of ME/CFS that relate to the shared disease experience between patients while also understanding each patients unique biology that create variation in disease experience and severity.

About Chris Armstrong, PhD

Chris Armstrong, PhD, is most well known for his research using metabolomics to observe biochemical alterations in ME/CFS patients. He began his work in this field at the University of Melbourne, beginning a PhD project to apply metabolomics to study Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and published his first ME/CFS metabolomics study on blood and urine in 2015.

Since then Chris has set up collaborative efforts to apply metabolomics to immunological experiments on ME/CFS, observing how metabolism may relate to immune cell function. He has also focused on longitudinal research in ME/CFS while looking to extend metabolic capabilities across the field of ME/CFS to help collate different patient groups.

Core Aims

Fundamental Philosophy

Current Studies Under Review

Nitrogen Hypothesis

Nitrogen Metabolism and Testing Nitrogen Hypothesis in ME/CFS STUDY AIM This project aims to test the nitrogen hypothesis, which is that damaging, nitrogen-containing by-products of …

Read More →

Pediatrics ME/CFS Deep Omics Profiling and Longitudinal Study

Pediatrics ME/CFS Deep Omics Profiling and Longitudinal Study STUDY AIM This proposal seeks to understand pathological mechanisms of paediatric ME/CFS (13 to 18 years old) …

Read More →

Characterizing B cells in ME/CFS

Characterizing B cells in ME/CFS STUDY AIM This study aims to broadly evaluate B cell subsets, metabolism, viability, receptors, and antibodies in people with ME/CFS. …

Read More →

Developing Condensed Precision Medicine Protocol for ME/CFS

Developing condensed precision research protocol for ME/CFS PROTOCOL AIM Establish a condensed personalized research protocol that can be used to characterize ME/CFS in individual patients …

Read More →

Developing Rapid System for Outlier Analysis in ME/CFS

Developing Rapid System for Outlier Analysis in ME/CFS PROTOCOL AIM Establish an analytical workflow for outlier analysis in ME/CFS to identify disease or symptom exacerbators …

Read More →

View our latest news

Newsletter February 2021

An Update from Chris Armstrong, Director, Melbourne ME/CFS Collaboration The Melbourne ME/CFS Collaboration is the fifth and newest OMF funded collaborative research center. After making

Read More »

CRC Collaborators

To carry out these ambitious projects, Dr. Armstrong is establishing networks and collaborations extending to USA, UK, Sweden, and other Australian institutions. 

University of Melbourne, Australia

Christopher Armstrong, PhD

Paul Gooley, PhD

Neil McGregor, PhD

David Ascher, PhD

Elisha Josev, PhD

Sarah Knight, PhD

Adam Scheinberg, MD

David Stroud, PhD

Stanford University, USA

Ronald Davis, PhD

Robert Phair, PhD

Laurel Crosby, PhD

Julie Wilhelmy

Amit Saha, PhD

Layla Cervantes

Anna Okumu

Mike Snyder, PhD

Uppsala University, Sweden

Jonas Bergquist, MD, PhD

Massachusetts General Hospital, USA

Ronald Tompkins, MD, ScD

Wenzhong Xiao, PhD

Michael VanElzakker, PhD

University of Montreal, Canada

Alain Moreau, PhD

Open Medicine Foundation

Linda Tannenbaum

UC San Diego, USA

Robert Naviaux, MD, PhD

University of Alabama Birmingham, USA

Jarred Younger, PhD

University College London, UK

Jo Cambridge, PhD

La Trobe University, Australia

Sarah Annesley, PhD

Paul Fisher, PhD

Daniel Missailidis

Learn about Our Other OMF Funded Collaborative Research Centers

Stay Informed

Be the first to hear our research news.

Subscribe Now.

No thanks

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

 

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.

BACKGROUND

In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.

THE STUDY

The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.

###

About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of five prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.

CONTACT:

Heather Ah San

Development and Communications Manager

1-650-242-8669

heather@omf.ngo